ReviewFrontiers in cardiovascular medicine2025
Insulin resistance and atrial fibrillation: from disease onset to post-ablation outcomes: a systematic review and meta-analysis.
Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association of cardiovascular-kidney-metabolic burden with recurrence after first ablation in patients with persistent atrial fibrillation.BMC cardiovascular disorders · 2026Article
- SPISE Index (Single-Point Insulin Sensitivity Estimator): A Long-Term Predictor of Recurrence in Elderly Patients with Atrial Fibrillation After Radiofrequency Ablation.Clinical interventions in aging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically evaluate the impact of insulin resistance (IR) on the risk of new-onset atrial fibrillation (AF) and post-ablation recurrence, and to elucidate underlying mechanisms and translational implications for early identification and precision management of high-risk populations. Methods: A comprehensive meta-analysis was conducted by integrating 30 high-quality cohort studies from multiple countries, incorporating IR markers such as TyG index and HOMA-IR. Random-effects models were used to estimate the association between IR and both AF incidence and ablation recurrence. Subgroup analyses, sensitivity analyses, meta-regression, and GRADE quality assessment were performed to explore heterogeneity and robustness. Mechanistic pathways were systematically summarized. This study was registered in PROSPERO (CRD420251142441). Results: Pooled results demonstrated that IR significantly increased the risk of new-onset AF (HR = 1.34, 95%CI: 1.24-1.46) and post-ablation recurrence (HR = 1.57, 95%CI: 1.39-1.78), with consistent effects across subgroups by country, IR index, study type, and follow-up. Mechanistic evidence revealed that IR promotes AF development and recurrence via enhanced inflammation, oxidative stress, atrial structural remodeling, and electrical abnormalities. IR-related indices showed higher clinical utility for risk stratification in Chinese and Asian populations. Meta-regression and sensitivity analyses confirmed the robustness of these findings. The quality of evidence was rated as moderate. Conclusion: Insulin resistance is an independent risk factor for both new-onset and recurrent AF. IR-related indices have translational value for early risk identification and personalized management. Incorporating IR assessment into AF management and prevention strategies-integrating metabolic and electrophysiological perspectives-may optimize long-term outcomes and provide a foundation for precision medicine and tailored follow-up in AF care. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420251142441, PROSPERO CRD420251142441.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.